Man Group
FATE icon

Man Group’s Fate Therapeutics FATE Stock Holding History

Man Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$516K Buy
430,073
+168,901
+65% +$206K ﹤0.01% 2074
2025
Q4 		$257K Buy
261,172
+41,514
+19% +$49.9K ﹤0.01% 2069
2025
Q3 		$277K Buy
+219,658
New +$237K ﹤0.01% 2030
2024
Q1 		– Sell
-252,676
Closed -$945K – 2159
2023
Q4 		$945K Buy
+252,676
New +$596K ﹤0.01% 1467
2023
Q3 		– Sell
-173,940
Closed -$576K – 1530
2023
Q2 		$828K Buy
+173,940
New +$960K ﹤0.01% 1448
2023
Q1 		– Sell
-93,837
Closed -$566K – 1583
2022
Q4 		$947K Buy
93,837
+76,537
+442% +$1.44M ﹤0.01% 1333
2022
Q3 		$388K Buy
+17,300
New +$500K ﹤0.01% 1595
2022
Q1 		– Sell
-12,430
Closed -$727K – 2221
2021
Q4 		$727K Buy
+12,430
New +$705K ﹤0.01% 1421
2021
Q2 		– Sell
-6,212
Closed -$512K – 1996
2021
Q1 		$512K Sell
6,212
-73,111
-92% -$7.01M ﹤0.01% 1471
2020
Q4 		$7.21M Sell
79,323
-25,977
-25% -$1.61M 0.03% 594
2020
Q3 		$4.21M Buy
105,300
+78,133
+288% +$2.73M 0.02% 899
2020
Q2 		$932K Buy
+27,167
New +$810K ﹤0.01% 1295

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Man Group's FATE Position: Q1 2026 in Review

Man Group increased its Fate Therapeutics (FATE) stake by 65% in Q1 2026, buying an estimated $206K and bringing the position to 430,073 shares worth $516K. The position accounts for ﹤0.01% of the portfolio, ranked #2074.

Man Group first reported a position in FATE in Q2 2020 and has held it in 12 quarters since. The position peaked at $7.21M in Q4 2020. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Man Group held 430,073 shares of Fate Therapeutics worth $516K as of Q1 2026.
  • Man Group bought 168,901 Fate Therapeutics shares in Q1 2026, an estimated $206K.
  • Fate Therapeutics made up ﹤0.01% of Man Group's portfolio in Q1 2026, its #2074 holding.
  • Man Group first reported a position in Fate Therapeutics in Q2 2020 and has held it in 12 quarters since.
  • Man Group's Fate Therapeutics position peaked at $7.21M in Q4 2020.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.